16.88
0.42 (2.55%)
| Previous Close | 16.46 |
| Open | 16.51 |
| Volume | 43,690,487 |
| Avg. Volume (3M) | 35,753,606 |
| Market Cap | 32,338,737,152 |
| Price / Earnings (TTM) | 22.51 |
| Price / Earnings (Forward) | 15.24 |
| Price / Sales | 2.15 |
| Price / Book | 3.02 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| TTM Dividend Yield | 1.21% |
| Profit Margin | 6.90% |
| Operating Margin (TTM) | 16.71% |
| Diluted EPS (TTM) | 0.560 |
| Quarterly Revenue Growth (YOY) | -3.90% |
| Quarterly Earnings Growth (YOY) | 8.80% |
| Total Debt/Equity (MRQ) | 88.04% |
| Current Ratio (MRQ) | 0.860 |
| Operating Cash Flow (TTM) | 1.91 B |
| Levered Free Cash Flow (TTM) | 1.79 B |
| Return on Assets (TTM) | 6.77% |
| Return on Equity (TTM) | 10.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Household & Personal Products (US) | Bearish | Bearish |
| Household & Personal Products (Global) | Bearish | Bearish | |
| Stock | Kenvue Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
|
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Investment Style | Mid Core |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 101.55% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 23.00 (Jefferies, 36.26%) | Buy |
| Median | 18.50 (9.60%) | |
| Low | 15.00 (Canaccord Genuity, -11.14%) | Hold |
| Average | 19.10 (13.15%) | |
| Total | 4 Buy, 6 Hold | |
| Avg. Price @ Call | 16.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 10 Nov 2025 | 18.00 (6.64%) | Hold | 16.77 |
| 01 Oct 2025 | 17.00 (0.71%) | Hold | 15.85 | |
| Canaccord Genuity | 29 Oct 2025 | 15.00 (-11.14%) | Hold | 14.31 |
| Jefferies | 27 Oct 2025 | 23.00 (36.26%) | Buy | 15.08 |
| JP Morgan | 10 Oct 2025 | 21.00 (24.41%) | Buy | 16.65 |
| Citigroup | 09 Oct 2025 | 17.00 (0.71%) | Hold | 16.84 |
| 16 Sep 2025 | 20.00 (18.48%) | Hold | 18.13 | |
| B of A Securities | 08 Oct 2025 | 21.00 (24.41%) | Buy | 16.08 |
| UBS | 08 Oct 2025 | 17.00 (0.71%) | Hold | 16.08 |
| Goldman Sachs | 02 Oct 2025 | 19.00 (12.56%) | Hold | 15.73 |
| Rothschild & Co | 26 Sep 2025 | 22.00 (30.33%) | Buy | 16.42 |
| Evercore ISI Group | 23 Sep 2025 | 18.00 (6.64%) | Hold | 17.24 |
| 08 Sep 2025 | 23.00 (36.26%) | Hold | 18.43 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Nov 2025 | Announcement | KVUE Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Kenvue to Kimberly-Clark |
| 03 Nov 2025 | Announcement | Kenvue Reports Third Quarter 2025 Results |
| 03 Nov 2025 | Announcement | Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader |
| 03 Nov 2025 | CNBC | Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant |
| 29 Oct 2025 | Announcement | Kenvue Declares Quarterly Cash Dividend |
| 27 Oct 2025 | Announcement | Kenvue to Announce Third Quarter 2025 Results on November 6, 2025 |
| 14 Oct 2025 | Announcement | Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI |
| 05 Sep 2025 | CNBC | Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy |
| TTM Dividend Yield | 1.21% |
| 2Y Average Dividend Yield | 2.83% |
| Payout Ratio | 145.54% |
| Expected Next Dividend Payment | Nov 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 12 Feb 2025 | 16 Jan 2025 | 26 Feb 2025 | 0.205 Cash |
| 13 Nov 2024 | 17 Oct 2024 | 27 Nov 2024 | 0.205 Cash |
| 14 Aug 2024 | 25 Jul 2024 | 28 Aug 2024 | 0.205 Cash |
| 07 May 2024 | 25 Apr 2024 | 22 May 2024 | 0.2 Cash |
| 13 Feb 2024 | 25 Jan 2024 | 28 Feb 2024 | 0.2 Cash |
| 07 Nov 2023 | 26 Oct 2023 | 22 Nov 2023 | 0.2 Cash |
| 25 Aug 2023 | 20 Jul 2023 | 07 Sep 2023 | 0.2 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.205 | 1 | 1.21 |
| 2024 | 0.810 | 4 | 3.79 |
| 2023 | 0.400 | 2 | 1.86 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |